Navigation Links
The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol
Date:11/6/2012

LDL receptors in the liver. Without PCSK9 bound to them, the LDL receptors can take up and remove LDL-C from the blood, recycle and remain available for binding additional LDL-C. The Amgen Phase 2 program for AMG 145 enrolled more than 2,000 patients across seven studies to evaluate the effects of AMG 145 across multiple patient populations who may benefit from additional cholesterol lowering treatment options. The Phase 2 program is evaluating the treatment of hyperlipidemia with AMG 145 in combination with statins, in patients with hyperlipidemia who cannot tolerate statins, as a stand-alone treatment in patients with hyperlipidemia, and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous and homozygous familial hypercholesterolemia.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
2. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
3. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
4. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
5. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
6. Publication of PrEP Trial Data Provides Clear Evidence that PrEP Works for Men and Women
7. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
8. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
9. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
10. International Spine Products Manufacturer Featured in Upcoming US Business Executive Publication - www.gsmedicalusa.com
11. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Zacks.com announces the list ... Zacks Equity Research analysts discuss the latest news and events ... the blog include the Hewlett-Packard (NYSE: HPQ - Free Report ... Bulkers, Inc. (NYSE: SB - Free Report ), GlaxoSmithKline ... International N.V. (NYSE: FI - Free Report ). ...
(Date:8/21/2014)... 21, 2014 InfinityQS International, Inc., the ... Intelligence , today announces Infusion Chicago, its 9 ... be held Oct. 9-10, 2014, at the Chicago ... showcase the necessity for implementing a quality system ... Intelligence to gain insight into production processes. Complimentary ...
(Date:8/21/2014)... , Aug. 21, 2014  The board of directors ... leading provider of clinical trial imaging solutions, today announced ... chief financial officer, effective immediately.  Mr. Groff has held ... 2013.  He joined VirtualScopics in January 2006 as an ... 2013. "When the board of VirtualScopics asked ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... FRANCISCO, June 22, 2011 Autonomy Corporation plc ... infrastructure software for the enterprise, today announced that the ... Autonomy,s flagship Web Content Management (WCM) platform, has twice ... Site Monitor performance report. The Swiss Pharma Site Monitor ...
... FALL RIVER, Mass., June 21, 2011 Millstone ... introduced an advanced version of its online inventory ... refinement, Millstone launched a new online, password-protected system ... place orders, and manage distribution.  Benefits of the ...
Cached Medicine Technology:Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 2Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 3Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 4Millstone Medical Outsourcing Introduces Advanced Version of Online Inventory Management System 2
(Date:8/22/2014)... (PRWEB) August 22, 2014 According ... Type & Application - Global Trends & Forecast ... with an analysis and forecast of the market ... to $38,729 million by 2019, at a significant ... market data tables and 44 figures spread through ...
(Date:8/22/2014)... Hallandale Beach, Florida (PRWEB) August 22, 2014 ... treatment for Lasik in Fort Lauderdale at the most ... patients get better eyesight through their advanced Lasik treatments. ... available worldwide and the Braverman Eye Center has been ... thousands of patients live a glasses-free and contact lenses-free ...
(Date:8/22/2014)... a wide range of epigenetic changesalterations in DNA across the ... with Crohn,s disease (CD), reports Inflammatory Bowel Diseases ... Foundation of America (CCFA). The journal is published ... Wolters Kluwer Health . , The study ... of the genome in children with CD, according to Professor ...
(Date:8/22/2014)... confused with lactose intolerance. However, these are two entirely ... lactose intolerance do not digest lactose properly because they ... of the potentially much more dangerous cow milk allergy, ... its own IgE antibodies. , According to statistics, about ... from a genuine milk allergy. Less adults are diagnosed ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
Breaking Medicine News(10 mins):Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3
... are warned of side effect that could hamper immigration ... widely used cancer drug capecitabine can cause people to ... they,re trying to enter the United States, an oncologist ... medical oncology at the National Cancer Centre in Singapore, ...
... learned at the Canadian-run military hospital in Kandahar, Afghanistan ... a London, Ontario physician who has served two tours ... professor in the Department of Surgery at the Schulich ... Western Ontario and a general surgeon at the London ...
... Recondo Technology, a leading provider of revenue ... today announced the firm,s selection as one ... Recondo as one of the top 100 companies ... http://www.newscom.com/cgi-bin/prnh/20090527/LA23009LOGO ) , (Logo: ...
... Johnson recognized by business leaders for vision, determination and ... Search America , a part of ... health care, today announced that its president, Daniel Johnson, ... & Young Entrepreneur of the Year(R) Award in Minnesota ...
... to develop new and more effective therapies to fight ... Team" of scientists and clinicians that is co-led by ... Department of Energy,s Lawrence Berkeley National Laboratory. , The ... Entertainment Industry Foundation charitable organization aimed at moving cancer ...
... Care Reform; Mark McClellan ModeratesWASHINGTON, May 27 ... to presenting comprehensive legislation to overhaul the nation,s ... Secretary Michael Leavitt and former Senate Majority Leader ... highlight the need for transparency and inclusion in ...
Cached Medicine News:Health News:Fingerprints May Vanish With Cancer Drug 2Health News:Sharing surgical lessons from the Canadian field hospital in Afghanistan 2Health News:Recondo Technology Wins Red Herring 100 North America Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 3Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 2Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 3Health News:NPC Newsmaker Program Hosts Briefing on Health Care Reform with Former HHS Secretary Michael Leavitt and Former Senate Majority Leader Tom Daschle 2
... are designed for the retraction of ... lesions. Reduced obstruction when working within ... range of blade sizes from 2 ... change and release, malleable material allows ...
The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us...
Telescopic Diamond-Dissectors for delicate sharp tissue preparation. Total/working lengths 220/240 mm with protective sleeve....
Epstein Curettes 3.0 mm, length 8" (203 mm)....
Medicine Products: